Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Haery, Leila ^a   Lugo Picó, Julián G ^a   Henry, Ryan A ^b   Andrews, Andrew J ^b   Gilmore, Thomas D ^a  

^a USA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

B cell lymphoma; H3 acetylation; Histone acetyltransferase; p300; REL; SUDHL2

Indexed keywords

ACETYLATION; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IMMUNOPRECIPITATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; P300-CBP TRANSCRIPTION FACTORS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84894311458     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-29     Document Type: Article

References (53)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276. 10.1182/blood-2005-06-2508, 1895348, 16150940.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511. 10.1038/35000501, 10676951.
3. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195. 10.1038/nature09730, 3271441, 21390126.
4. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011, 43:830-837. 10.1038/ng.892, 3297422, 21804550.
5. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303. 10.1038/nature10351, 3210554, 21796119.
6. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernandez-Lemus E, Schwarz-Cruz Y, Celis A, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012, 109:3879-3884. 10.1073/pnas.1121343109, 3309757, 22343534.
7. Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest 2010, 120:4569-4582.
8. Giordano A, Avantaggiati ML. p300 and CBP: partners for life and death. J Cell Physiol 1999, 181:218-230. 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5, 10497301.
9. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A 1997, 94:2927-2932. 10.1073/pnas.94.7.2927, 20299, 9096323.
10. Garbati MR, Alço G, Gilmore TD. Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Lett 2010, 291:237-245. 10.1016/j.canlet.2009.10.018, 2849871, 19948376.
11. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997, 89:1175-1184. 10.1016/S0092-8674(00)80304-9, 9215639.
12. Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE. Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. Biochemistry 2009, 48:2115-2124. 10.1021/bi802055v, 2765525, 19220000.
13. Sartorelli V, Huang J, Hamamori Y, Kedes L. Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol 1997, 17:1010-1026. 231826, 9001254.
14. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000, 6:1335-1340. 10.1038/82146, 11100117.
15. Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci U S A 2000, 97:1020-1025. 10.1073/pnas.97.3.1020, 15508, 10655477.
16. Yang C, Shapiro LH, Rivera M, Kumar A, Brindle PK. A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions. Mol Cell Biol 1998, 18:2218-2229. 121466, 9528793.
17. Abraham SE, Lobo S, Yaciuk P, Wang HG, Moran E. p300, and p300-associated proteins, are components of TATA-binding protein (TBP) complexes. Oncogene 1993, 8:1639-1647.
18. Garbati MR, Thompson RC, Haery L, Gilmore TD. A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Lett 2011, 302:76-83. 10.1016/j.canlet.2010.12.018, 3042717, 21232847.
19. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, Delhanty JD, Ponder BA, Kouzarides T, Caldas C. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000, 24:300-303. 10.1038/73536, 10700188.
20. Ionov Y, Matsui S, Cowell JK. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc Natl Acad Sci U S A 2004, 101:1273-1278. 10.1073/pnas.0307276101, 337043, 14732695.
21. Kimbrel EA, Lemieux ME, Xia X, Davis TN, Rebel VI, Kung AL. Systematic in vivo structure-function analysis of p300 in hematopoiesis. Blood 2009, 114:4804-4812. 10.1182/blood-2009-04-217794, 19822904.
22. Eckner R, Yao TP, Oldread E, Livingston DM. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev 1996, 10:2478-2490. 10.1101/gad.10.19.2478, 8843199.
23. Li M, Damania B, Alvarez X, Ogryzko V, Ozato K, Jung JU. Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. Mol Cell Biol 2000, 20:8254-8263. 10.1128/MCB.20.21.8254-8263.2000, 86434, 11027294.
24. Wang L, Grossman SR, Kieff E. Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci U S A 2000, 97:430-435. 10.1073/pnas.97.1.430, 26680, 10618435.
25. Cotter MA, Robertson ES. Modulation of histone acetyltransferase activity through interaction of Epstein-Barr nuclear antigen 3C with prothymosin alpha. Mol Cell Biol 2000, 20:5722-5735. 10.1128/MCB.20.15.5722-5735.2000, 86050, 10891508.
26. Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene 2008, 27:5717-5728. 10.1038/onc.2008.181, 18542060.
27. Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction pathway. Oncogene 2002, 21:8759-8768. 10.1038/sj.onc.1206033, 12483529.
28. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721. 10.1038/nature07968, 2973325, 19412164.
29. von Mikecz A, Zhang S, Montminy M, Tan EM, Hemmerich P. CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus. J Cell Biol 2000, 150:265-273. 10.1083/jcb.150.1.265, 2185550, 10893273.
30. Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, Howard BH, Kedes L, Wang JY, Graessmann A, Nakatani Y, Levrero M. Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1997, 1:35-45. 10.1016/S1097-2765(00)80005-2, 9659901.
31. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 2004, 430:694-699. 10.1038/nature02794, 15258597.
32. Krikos A, Laherty CD, Dixit VM. Transcriptional activation of the tumor necrosis factor α-inducible zinc finger protein, A20, is mediated by κB elements. J Biol Chem 1992, 267:17971-17976.
33. Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev 2012, 246:359-378. 10.1111/j.1600-065X.2012.01105.x, 22435566.
34. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 1999, 18:6925-6937. 10.1038/sj.onc.1203222, 10602467.
35. Luebben WR, Sharma N, Nyborg JK. Nucleosome eviction and activated transcription require p300 acetylation of histone H3 lysine 14. Proc Natl Acad Sci U S A 2010, 107:19254-19259. 10.1073/pnas.1009650107, 2984149, 20974913.
36. Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ. Adenovirus small e1a alters global patterns of histone modification. Science 2008, 321:1084-1085. 10.1126/science.1155544, 2756290, 18719283.
37. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK. Epigenetic reprogramming by adenovirus e1a. Science 2008, 321:1086-1088. 10.1126/science.1155546, 2693122, 18719284.
38. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266. 10.1038/nature03672, 15988529.
39. Kueh AJ, Dixon MP, Voss AK, Thomas T. HBO1 is required for H3K14 acetylation and normal transcriptional activity during embryonic development. Mol Cell Biol 2011, 31:845-860. 10.1128/MCB.00159-10, 3028655, 21149574.
40. Love IM, Sekaric P, Shi D, Grossman SR, Androphy EJ. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle 2012, 11:2458-2466. 10.4161/cc.20864, 3404877, 22713239.
41. Thompson RC, Vardinogiannis I, Gilmore TD. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One 2013, 8:e62822. 10.1371/journal.pone.0062822, 3647059, 23667527.
42. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual 1989, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2.
43. Starczynowski DT, Reynolds JG, Gilmore TD. Mutations of tumor necrosis factor α-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene 2005, 24:7355-7368. 10.1038/sj.onc.1208902, 16027730.
44. Sun CC, Thorley-Lawson DA. Plasma cell-specific transcription factor XBP-1 s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol 2007, 81:13566-13577. 10.1128/JVI.01055-07, 2168822, 17898050.
45. Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrest BA, Denis GV. Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer 2009, 124:473-482. 10.1002/ijc.23946, 2888476, 19003960.
46. Liang M-C, Bardhan S, Porco JA, Gilmore TD. The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IkappaBalpha-deficient diffuse large B-cell lymphoma cell line. Cancer Lett 2006, 241:69-78. 10.1016/j.canlet.2005.10.004, 16289774.
47. ImageJ. [http://imagej.nih.gov/ij/].
48. Chin M, Herscovitch M, Zhang N, Waxman DJ, Gilmore TD. Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene 2009, 28:2100-2111. 10.1038/onc.2009.74, 2796798, 19377508.
49. Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat Protoc 2006, 1:729-748. 10.1038/nprot.2006.98, 3004291, 17406303.
50. Amir-Zilberstein L, Ainbinder E, Toube L, Yamaguchi Y, Handa H, Dikstein R. Differential regulation of NF-κB by elongation factors is determined by core promoter type. Mol Cell Biol 2007, 27:5246-5259. 10.1128/MCB.00586-07, 1951948, 17502349.
51. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
52. Garcia BA, Mollah S, Ueberheide BM, Busby SA, Muratore TL, Shabanowitz J, Hunt DF. Chemical derivatization of histones for facilitated analysis by mass spectrometry. Nat Protoc 2007, 2:933-938. 10.1038/nprot.2007.106, 17446892.
53. Kuo YM, Andrews AJ. Quantitating the specificity and selectivity of Gcn5-mediated acetylation of histone H3. PLoS One 2013, 8:e54896. 10.1371/journal.pone.0054896, 3578832, 23437046.